New trial for rare inherited disease

The first patient has been recruited for a trial of a new treatment for the inherited condition Sanfilippo Disease, it was announced today.

Sanfilippo Disease is a progressive, life-threatening metabolism disorder involving deafness, hyperactivity and behavioural problems, progressive developmental delay, and seizures. It affects about one in 85,000 people in the UK. There is currently no effective treatment and patients usually die in late childhood or early adulthood.

Now a four year old patient from Sunderland, called Jack Baird, is to take part in a study of a new treatment.

It is based on research from Manchester University, UK, and will use high doses of the treatment Genistein Aglycone. This substance may help by blocking the production of heparan sulphate, which is present in excess levels in the brain cells of people with Sanfilippo Disease.

The therapy aims to compensate for the lack the enzyme that usually breaks down heparan sulphate. In this way, it may protect brain cells from damage. Although Genistein is found in soya beans, a synthetic version called Genistein Aglycone will be used in the study as it is easier for the gut to absorb. High doses are to be given, as previous research has found that low doses of Genistein are not effective in the brain.

Researcher Dr Brian Bigger said: "It is fantastic to see a treatment we developed, in collaboration with clinicians, reach the point where we can test its effectiveness in patients. This new study is the first to test the effectiveness of the higher doses of Genistein, which are thought to be of the strength required to see an effect in the brain.

"We are looking forward to analysing the results of the trial and hope that the treatment will benefit patients."

Fellow researcher Dr Simon Jones, from Saint Mary’s Hospital, Manchester, added: "It’s important for us to undertake research in rare diseases, like Sanfilippo Disease, so that we can provide these patients with the best possible care. During the later stages of the disease, patients experience seizures, become wheelchair bound and can have trouble swallowing.

“This new study is open to children aged two to 15 years old. Patients taking part in the study will receive either Genistein Aglycone or placebo (an inactive substance that looks like the treatment) with food, over a period of 12 months.

After 12 months all children will receive Genistein Aglycone for a further 12 months."

Dr Bigger was discussing the project today at the International Symposium on Mucopolysaccharidoses and related disease this week in Costa Do Sauipe, Bahia, Brazil.

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index